Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on September 6, 2016. The filing discloses a corporate action regarding the company's 6% Convertible Exchangeable Preferred Stock.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is the declaration of a quarterly cash dividend of $0.15 per share on the Preferred Stock.
Material Changes
The material event reported is the Board of Directors' declaration of a quarterly cash dividend. This dividend is payable on November 1, 2016, to holders of record as of the close of business on October 17, 2016.
Guidance, Outlook, and Risks
Management noted that the Board considered financial analysis and surplus determinations before declaring the dividend. The filing explicitly states there is no assurance that future quarterly dividends will be declared, as the Board will analyze the advisability of such declarations in future quarters.
Investor Verification Checklist
- Verify the record date of October 17, 2016, to confirm eligibility for the $0.15 per share dividend.
- Confirm the payment date of November 1, 2016, for the dividend distribution.
- Review the company's latest financial statements to assess the surplus and liquidity position supporting this dividend.
- Note that future dividend declarations are not guaranteed and depend on future Board analysis.